| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/07/2022 | -18.4% | Jefferies | $78 → $53 | Downgrades | Hold → Underperform |
| 04/27/2022 | 17.01% | DA Davidson | $86 → $76 | Maintains | Neutral |
| 04/14/2022 | 32.41% | DA Davidson | → $86 | Initiates Coverage On | → Neutral |
| 02/10/2021 | 94% | Roth Capital | $107 → $126 | Maintains | Buy |
| 12/17/2020 | 64.74% | Roth Capital | → $107 | Initiates Coverage On | → Buy |
| 08/22/2019 | 0.08% | Jefferies | → $65 | Initiates Coverage On | → Hold |
| 07/03/2019 | 7.78% | Sidoti & Co. | $108 → $70 | Downgrades | Buy → Neutral |
| 04/16/2019 | — | Tigress Financial | Initiates Coverage On | → Buy | |
| 04/23/2018 | — | Pivotal Research | Downgrades | Buy → Hold | |
| 01/24/2018 | — | Sidoti & Co. | Downgrades | Buy → Neutral |
Usana Health Sciences Questions & Answers
The latest price target for Usana Health Sciences (NYSE: USNA) was reported by Jefferies on July 7, 2022. The analyst firm set a price target for $53.00 expecting USNA to fall to within 12 months (a possible -18.40% downside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Usana Health Sciences (NYSE: USNA) was provided by Jefferies, and Usana Health Sciences downgraded their underperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Usana Health Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Usana Health Sciences was filed on July 7, 2022 so you should expect the next rating to be made available sometime around July 7, 2023.
While ratings are subjective and will change, the latest Usana Health Sciences (USNA) rating was a downgraded with a price target of $78.00 to $53.00. The current price Usana Health Sciences (USNA) is trading at is $64.95, which is out of the analyst's predicted range.